Hematological findings in coronavirus disease 2019: indications of progression of disease Xiaoqing LiuRun ZhangGuangsheng He Review Article 03 June 2020 Pages: 1421 - 1428
Antifungal prophylaxis and novel drugs in acute myeloid leukemia: the midostaurin and posaconazole dilemma Jannik StemlerPhilipp KoehlerOliver A. Cornely Review Article Open access 08 June 2020 Pages: 1429 - 1440
Modern management of splenomegaly in patients with myelofibrosis Douglas TremblayMyron SchwartzJohn Mascarenhas Review Article 17 May 2020 Pages: 1441 - 1451
Functional polymorphisms of BCL11A and HBS1L-MYB genes affect both fetal hemoglobin level and clinical outcomes in a cohort of children with sickle cell anemia Rahyssa Rodrigues SalesAndré Rolim BelisárioMarcos Borato Viana Original Article 23 May 2020 Pages: 1453 - 1463
Fifteen years of newborn sickle cell disease screening in Madrid, Spain: an emerging disease in a European country Marina García-MorínEduardo J. Bardón-CanchoElena Cela Original Article 26 May 2020 Pages: 1465 - 1474
Genotypic-phenotypic heterogeneity of δβ-thalassemia and hereditary persistence of fetal hemoglobin (HPFH) in India Priya HariharanPooja KishnaniAnita Nadkarni Original Article 10 June 2020 Pages: 1475 - 1483
Immunosuppression therapy is effective for both acquired tumor-associated and primary pure red cell aplasia: a match pair case-control study Zesong ChenMiao ChenBing Han Original Article 01 June 2020 Pages: 1485 - 1491
Nationwide study of paroxysmal nocturnal hemoglobinuria in South Korea: paradox of eculizumab Ka-Won KangHyemi MoonYong Park Original Article 15 June 2020 Pages: 1493 - 1503
Baseline clinical characteristics and disease burden in patients with paroxysmal nocturnal hemoglobinuria (PNH): updated analysis from the International PNH Registry Hubert SchrezenmeierAlexander RöthJaroslaw P. Maciejewski Original Article Open access 10 May 2020 Pages: 1505 - 1514
Dynamics of hematopoiesis is disrupted by impaired hematopoietic microenvironment in a mouse model of hemophagocytic lymphohistiocytosis Isao TsuboiTomonori HaradaShin Aizawa Original Article 06 June 2020 Pages: 1515 - 1523
Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors Olga MulasGiovanni CaocciGiorgio La Nasa Original Article 30 May 2020 Pages: 1525 - 1530
LPS-induced expression and release of monocyte tissue factor in patients with haemophilia Katharina HolsteinAnna MatysiakFlorian Langer Original Article Open access 19 May 2020 Pages: 1531 - 1542
Hematological malignancies in Ukraine in post-Chernobyl era: sources of data and their preliminary analysis Stella V. KovalDaniil F. GluzmanYaroslava I. Vyhovska Original Article 19 May 2020 Pages: 1543 - 1550
Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemia Heiko BeckerDietmar PfeiferMichael Lübbert Original Article Open access 06 June 2020 Pages: 1551 - 1560
A novel NAP1L4/NUTM1 fusion arising from translocation t(11;15)(p15;q12) in a myeloid neoplasm with eosinophilia and rearrangement of PDGFRA highlights an unusual clinical feature and therapeutic reaction Zhao ChengYunya LuoGuangsen Zhang Original Article 26 May 2020 Pages: 1561 - 1564
Lymphopenia at diagnosis predicts survival of patients with immunodeficiency-associated lymphoproliferative disorders Mizuki WatanabeJunya KandaAkifumi Takaori-Kondo Original Article 20 May 2020 Pages: 1565 - 1573
Hodgkin lymphoma-associated hemophagocytic lymphohistiocytosis—a dangerous disease Zhili JinYini WangZhao Wang Original Article 04 June 2020 Pages: 1575 - 1581
The interval between progression and therapy initiation is the key prognostic parameter in relapsing diffuse large B cell lymphoma: analysis from the Czech Lymphoma Study Group database (NIHIL) Andrea JanikovaJozef MichalkaMarek Trneny Original Article 06 June 2020 Pages: 1583 - 1594
Progression of disease within 2 years (POD24) is a clinically relevant endpoint to identify high-risk follicular lymphoma patients in real life Clara SortaisAnne LokSteven Le Gouill Original Article 16 May 2020 Pages: 1595 - 1604
R-CHOP appears to be the best first-line treatment for second primary diffuse large B cell lymphoma: a cancer registry study T. SystchenkoG. DefossezP. Ingrand Original Article 25 May 2020 Pages: 1605 - 1613
Improved time to treatment failure and survival in ibrutinib-treated malignancies with a pharmaceutical care program: an observational cohort study Jeremie ZerbitSylvie ChevretCatherine Thieblemont Original Article Open access 01 June 2020 Pages: 1615 - 1625
Results of R-ESHAP as salvage therapy in refractory/relapsed follicular lymphoma: a real-world experience on behalf of GELCAB group A. MuntañolaT. BaumannJ. M. Sancho Original Article 25 May 2020 Pages: 1627 - 1634
Outcome of stem cell transplantation for Waldenström’s macroglobulinemia: analysis of the Japan Society for Hematopoietic Cell Transplantation (JSHCT) Lymphoma Working Group Masatoshi SakuraiTakehiko MoriRitsuro Suzuki Original Article 18 May 2020 Pages: 1635 - 1642
Comparison of central nervous system relapse outcomes following haploidentical vs identical-sibling transplant for acute lymphoblastic leukemia Qi ChenXin ZhaoXiao-hui Zhang Original Article 26 May 2020 Pages: 1643 - 1653
Geriatric nutritional risk index as a useful prognostic factor in second allogeneic hematopoietic stem cell transplantation Satoshi KaitoAtsushi WadaNoriko Doki Original Article 10 June 2020 Pages: 1655 - 1665
Safe administration of granulocyte colony-stimulating factor (G-CSF) to a patient with G-CSF–producing multiple myeloma Taku KikuchiJun KatoTakehiko Mori Letter to the Editor 06 June 2020 Pages: 1667 - 1668
Acquired amegakaryocytic thrombocytopenic purpura possibly induced by anti-PD-1 antibody Satoshi IyamaK. TakadaM. Kobune Letter to the Editor 04 May 2020 Pages: 1669 - 1670
Uterine myeloid sarcoma Giovanni MartinoMagda ZanelliStefano Ascani Letter to the Editor 04 May 2020 Pages: 1671 - 1672
Autoimmune thrombotic thrombocytopenic purpura (TTP) associated with COVID-19 Nil AlbiolRahinatu AwolRodrigo Martino Letter to the Editor 28 May 2020 Pages: 1673 - 1674
Could ruxolitinib be effective in patients with COVID-19 infection at risk of acute respiratory distress syndrome (ARDS)? Giovanni CaocciGiorgio La Nasa Letter to the Editor 14 May 2020 Pages: 1675 - 1676
SARS-CoV-2 impact in a community-based hematological ward in an Italian Red Zone Giuseppe VisaniMartina ChiarucciAlessandro Isidori Letter to the Editor 13 June 2020 Pages: 1677 - 1678
COVID-19 infection associated with autoimmune hemolytic anemia Antoine CapesSarah BaillyPierre-François Laterre Letter to the Editor 16 June 2020 Pages: 1679 - 1680